This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through March 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
Zacks News
Should You Invest in the Vanguard Health Care Index Fund ETF Shares (VHT)?
by Zacks Equity Research
Sector ETF report for VHT
Healthcare ETFs in Spotlight Amid Eli Lily's $2.8B AI Drug Move
by Aparajita Dutta
Eli Lilly's $2.75B AI drug deal with Insilico spotlights healthcare ETFs as investors seek diversified exposure to the fast-growing AI-driven pharma space.
Stagflation Scare? ETFs May Help Protect Your Portfolio
by Yashwardhan Jain
Are stagflation risks returning as oil-driven inflation rises amid Middle East tensions? Here's how ETFs can help defend portfolios.
Middle East Turmoil and U.S. Debt Surge: ETFs in Focus
by Yashwardhan Jain
With U.S. budget deficits and already elevated debt, the ongoing Middle East war could worsen the fiscal outlook, making defensive ETF strategies worth considering for stability.
ETFs to Play as Oil Surges Past $110 on Middle East Conflict
by Sanghamitra Saha
Oil above $110 amid Middle East conflict is rattling markets. Here are ETF strategies -- from dividends and defensives to commodities -- that could help navigate the volatility.
Should You Invest in the Vanguard Health Care ETF (VHT)?
by Zacks Equity Research
Sector ETF report for VHT
ETFs to Play as Investors Chase Diversification Amid Tech Rout
by Yashwardhan Jain
From "software-mageddon" to rising AI capex pressuring Big Tech, diversification via defensive and global ETFs gains focus.
Healthcare ETFs in Focus as UnitedHealth Rises 4% Post Mixed Q4 Results
by Aparajita Dutta
Healthcare ETFs draw attention as UNH climbs 4% on mixed Q4 results, a better 2026 cost outlook, and rising concerns over Medicaid pressure.
3 Healthcare ETFs to Buy as Flat Medicare Rate Proposal Hits Insurers
by Aparajita Dutta
Flat Medicare Advantage rate hikes hit insurers hard, but diversified healthcare ETFs may help investors weather the policy shock.
ETFs to Buy Post JNJ's Q4 Earnings Surprise & Bullish Cash Flow View
by Aparajita Dutta
JNJ beat Q4 earnings and sales estimates and sees 2026 free cash flow rising to $21B, making healthcare ETFs a safer way to play its momentum.